CMG Pharmaceutical Co., Ltd.

KOSDAQ:A058820 Stock Report

Market Cap: ₩265.1b

CMG Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

CMG Pharmaceutical has been growing earnings at an average annual rate of 3.4%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 10.1% per year. CMG Pharmaceutical's return on equity is 1.5%, and it has net margins of 3.1%.

Key information

3.4%

Earnings growth rate

-1.6%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate10.1%
Return on equity1.5%
Net Margin3.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

There May Be Reason For Hope In CMG Pharmaceutical's (KOSDAQ:058820) Disappointing Earnings

Nov 20
There May Be Reason For Hope In CMG Pharmaceutical's (KOSDAQ:058820) Disappointing Earnings

CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong Factors

Mar 27
CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong Factors

Recent updates

There May Be Reason For Hope In CMG Pharmaceutical's (KOSDAQ:058820) Disappointing Earnings

Nov 20
There May Be Reason For Hope In CMG Pharmaceutical's (KOSDAQ:058820) Disappointing Earnings

CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong Factors

Mar 27
CMG Pharmaceutical's (KOSDAQ:058820) Solid Earnings Are Supported By Other Strong Factors

Did You Participate In Any Of CMG Pharmaceutical's (KOSDAQ:058820) Fantastic 203% Return ?

Dec 28
Did You Participate In Any Of CMG Pharmaceutical's (KOSDAQ:058820) Fantastic 203% Return ?

Revenue & Expenses Breakdown

How CMG Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A058820 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2494,3642,89537,1491,110
30 Jun 2493,1878,28436,3311,162
31 Mar 2493,7666,00036,4651,490
31 Dec 2393,9076,45535,6862,181
30 Sep 2393,7194,05535,8252,901
30 Jun 2391,3815,85434,7863,425
31 Mar 2386,0912,11833,2203,619
31 Dec 2282,197-38832,1213,312
31 Mar 2060,0443,74423,7092,121
31 Dec 1958,6233,05122,6511,993
30 Sep 1956,0336,76121,2371,631
30 Jun 1953,3405,33920,0081,430
31 Mar 1951,4405,63018,891920
31 Dec 1849,8656,06518,019778
30 Sep 1847,1642,30816,7622,188
30 Jun 1845,9873,58915,6542,131
31 Mar 1843,7253,60914,2991,722
31 Dec 1741,5362,83513,5091,796
30 Sep 1739,6592,22812,7581,387
30 Jun 1736,7711,88911,7571,350
31 Mar 1734,79078611,0031,647
31 Dec 1632,97078910,4511,410
30 Sep 1631,530-1,83310,989822
30 Jun 1630,312-2,59611,547765
31 Mar 1628,555-3,64711,645756
31 Dec 1527,042-3,64910,832832
30 Sep 1525,389-8289,126320
30 Jun 1524,276-8347,925281
31 Mar 1523,046-557,348241
31 Dec 1422,7531587,338117
30 Sep 1426,3491028,271223
30 Jun 1425,7083868,355200
31 Mar 1421,0695756,912169
31 Dec 1320,4023116,561134

Quality Earnings: A058820 has a large one-off loss of ₩3.4B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: A058820's current net profit margins (3.1%) are lower than last year (4.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A058820's earnings have grown by 3.4% per year over the past 5 years.

Accelerating Growth: A058820's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A058820 had negative earnings growth (-28.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (22%).


Return on Equity

High ROE: A058820's Return on Equity (1.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies